Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 737 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR FDA Approvals Bring New Options for Older Patients with AML December 27, 2018 Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... August 27, 2021 A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... April 26, 2024 Load more HOT NEWS What to Know About Navigating Your Cancer Care During An Extreme... FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... Foodie Friday: It’s Berry Season!
